Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Abulhul, EsamMcDonald, Kenneth
Martos, Ramon
Phelan, Dermot
Spiers, J Paul
Hennessy, Martina
Baugh, John
Watson, Chris
O'Loughlin, Christina
Ledwidge, Mark
Affiliation
HF Unit, St Vincent's University Hospital, Elm Park, Dublin, Ireland.Issue Date
2012-01MeSH
AgedAged, 80 and over
Analysis of Variance
Biological Markers
Chi-Square Distribution
Cholesterol
Collagen
Collagen Type I
Down-Regulation
Female
Heart Failure, Systolic
Heptanoic Acids
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Inflammation Mediators
Ireland
Male
Middle Aged
Natriuretic Peptide, Brain
Peptide Fragments
Peptides
Procollagen
Prospective Studies
Pyrroles
Recovery of Function
Stroke Volume
Time Factors
Treatment Outcome
Up-Regulation
Ventricular Function, Left
Metadata
Show full item recordCitation
Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide. 2012, 34 (1):91-100 Clin TherJournal
Clinical therapeuticsDOI
10.1016/j.clinthera.2011.11.002PubMed ID
22154198Abstract
The role of statin therapy in heart failure (HF) is unclear. The amino-terminal propeptide of procollagen type III (PIIINP) predicts outcome in HF, and yet there are conflicting reports of statin therapy effects on PIIINP.Item Type
ArticleLanguage
enISSN
1879-114Xae974a485f413a2113503eed53cd6c53
10.1016/j.clinthera.2011.11.002
Scopus Count
Collections
Related articles
- The effects of atorvastatin (10 mg) on systemic inflammation in heart failure.
- Authors: Mozaffarian D, Minami E, Letterer RA, Lawler RL, McDonald GB, Levy WC
- Issue date: 2005 Dec 15
- Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction.
- Authors: de Denus S, Lavoie J, Ducharme A, O'Meara E, Racine N, Sirois MG, Neagoe PE, Zhu L, Rouleau JL, White M
- Issue date: 2012 Jan-Feb
- The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy.
- Authors: Bielecka-Dabrowa A, Goch JH, Mikhailidis DP, Rysz J, Maciejewski M, Banach M
- Issue date: 2009 Dec
- Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study.
- Authors: Yamada T, Node K, Mine T, Morita T, Kioka H, Tsukamoto Y, Tamaki S, Masuda M, Okuda K, Fukunami M
- Issue date: 2007 Jun
- Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
- Authors: Lopez-Andrès N, Rossignol P, Iraqi W, Fay R, Nuée J, Ghio S, Cleland JG, Zannad F, Lacolley P
- Issue date: 2012 Jan